Sudeep Pharma Ltd (SUDEEPPHRM) is currently trading at 1,140.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Sudeep Pharma Limited is a technology‑led manufacturer of excipients and specialty ingredients serving pharmaceutical, food and nutrition industries, with in‑house developed technologies, regulatory certifications (including US‑FDA) and a growing advanced‑materials arm (Sudeep Advanced Materials) focused on battery‑grade iron phosphate for LFP/LMFP markets. Q3 FY26 results show strong operational momentum: consolidated total income rose 52% YoY to Rs.179.2 crore with EBITDA of Rs.66.8 crore (37.3% margin) and PAT of Rs.47.7 crore (26.6% margin), driven by specialty ingredients strength, NSS contribution, and export growth which now represents ~62% of revenues for the quarter. Management is executing a clear capacity roadmap: Nandesari greenfield (51,200 MT, ~Rs.150 crore) commissioning by Q4 FY26 and Dahej battery materials Phase‑1 (25,000 MT, ~Rs.300 crore) targeted for early CY27, indicating a strategic pivot into high‑growth battery materials while expanding core pharma and specialty capacities. Sudeep’s battery strategy positions it as an early large non‑Chinese LFP supplier: the company reports 34 battery value‑chain customers, 26 approvals, multiple MoUs and commercial orders from upgraded capacity, leveraging a proprietary ‘green chemistry’ claim and port proximity to serve global OEMs and CAM producers. Product and regulatory moats are meaningful: 6 proprietary technologies, 420 R&D projects, multiple global certifications (FDA, EDQM, EXCiPACT) and long customer relationships (average >7 years for top customers) underpin pricing power, repeat business (84% repeat revenue) and faster entry into regulated markets such as Europe and North America.

Over the past 52 weeks, Sudeep Pharma Ltd has traded between a low of ₹524.95 and a high of ₹1,376.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Sudeep Pharma Ltd has a market capitalization of approximately 13,560.61. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Sudeep Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 73.86 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 13,560.61 Cr, Sudeep Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Sudeep Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Sudeep Pharma Ltd is 73.86. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The earnings call is scheduled for Wednesday, August 5, 2026 at 11:00 AM IST.